Kanjinti Reviewers
Executive Summary
US FDA staff who participated in the review and approval of trastuzumab-anns, Amgen’s biosimilar to Herceptin.
You may also be interested in...
Kanjinti’s Path To Market Complicated By GMP Issues, Reference Product Drift
US FDA licensure of Amgen’s biosimilar to Herceptin was delayed by a complete response letter citing product manufacturing facility deficiencies; review documents discuss how drift in Genentech's reference product impacted the biosimilar program's analytical and clinical data.
Kanjinti Clinical Development Timeline
Chronicle of the development and review of Amgen’s biosimilar to Genentech’s Herceptin.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.